MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 462501 | Name: Rezvilutamide
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Rezvilutamide, also known as SHR3680, is a novel androgen-receptor inhibitor with low blood-brain barrier penetration. Rezvilutamide has shown potent antitumour activity against metastatic castration-resistant prostate cancer. I

Chemical Structure

Rezvilutamide
Rezvilutamide
CAS#1572045-62-5

Theoretical Analysis

MedKoo Cat#: 462501

Name: Rezvilutamide

CAS#: 1572045-62-5

Chemical Formula: C22H20F3N3O4S

Exact Mass: 479.1127

Molecular Weight: 479.47

Elemental Analysis: C, 55.11; H, 4.20; F, 11.89; N, 8.76; O, 13.35; S, 6.69

Price and Availability

Size Price Availability Quantity
5mg USD 550.00 2 Weeks
10mg USD 950.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Rezvilutamide; SHR3680; SHR-3680; SHR 3680;
IUPAC/Chemical Name
4-(3-{4-[(2S)-2,3-dihydroxypropoxy]phenyl}-4,4-dimethyl-5-oxo-2-sulfanylideneimidazolidin-1-yl)-2 (trifluoromethyl)benzonitrile antiandrogen
InChi Key
KRBMOYIWQCZVHA-INIZCTEOSA-N
InChi Code
InChI=1S/C22H20F3N3O4S/c1-21(2)19(31)27(15-4-3-13(10-26)18(9-15)22(23,24)25)20(33)28(21)14-5-7-17(8-6-14)32-12-16(30)11-29/h3-9,16,29-30H,11-12H2,1-2H3/t16-/m0/s1
SMILES Code
N#CC1=CC=C(N(C(N(C2=CC=C(OC[C@@H](O)CO)C=C2)C3(C)C)=S)C3=O)C=C1C(F)(F)F
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 479.47 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Ding H, Li S, Xu X, Xu W, He C, Xin W, Zhan Z, Fang L. Cost-effectiveness analysis of rezvilutamide versus bicalutamide in the treatment of metastatic hormone-sensitive prostate cancer. BMJ Open. 2024 Jul 13;14(7):e073170. doi: 10.1136/bmjopen-2023-073170. PMID: 39002960; PMCID: PMC11253765. 2: Zhang C, Ren J, Kang Y, Chang D. Case report and literature review of rezvilutamide in the treatment of hormone-sensitive prostate cancer. Front Oncol. 2024 Mar 21;14:1374039. doi: 10.3389/fonc.2024.1374039. PMID: 38577344; PMCID: PMC10991726. 3: Wu H, Sun L, Feng R, Zhang H, Tang K, Wang S, Nie J. Cost-effectiveness of rezvilutamide versus bicalutamide and androgen-deprivation therapy in patients with highvolume, metastatic, hormone-sensitive prostate cancer. Front Pharmacol. 2024 Jan 9;14:1269129. doi: 10.3389/fphar.2023.1269129. PMID: 38264528; PMCID: PMC10803462. 4: Lee YS, Kim SH, Tae JH, Chang IH, Kim TH, Myung SC, Kim M, Nguyen TT, Choi J, Kim JH, Kim JW, Choi SY. Oral chemotherapeutic agents in metastatic hormone- sensitive prostate cancer: A network meta-analysis of randomized controlled trials. Prostate Int. 2023 Sep;11(3):159-166. doi: 10.1016/j.prnil.2023.06.003. Epub 2023 Jul 4. PMID: 37745904; PMCID: PMC10513908. 5: Vaishampayan U. Global efficacy and clinical application of androgen receptor inhibitors in metastatic prostate cancer. Chin Clin Oncol. 2023 Dec;12(6):61. doi: 10.21037/cco-23-59. Epub 2023 Sep 6. PMID: 37691348. 6: Zhou Z, Liu S, Mei J, Liu T, Liu F, Zhang G. Systemic therapies for high- volume metastatic hormone-sensitive prostate cancer: a network meta-analysis. Acta Oncol. 2023 Sep;62(9):1083-1090. doi: 10.1080/0284186X.2023.2241985. Epub 2023 Aug 7. PMID: 37548225. 7: Singh K. Rezvilutamide for metastatic castration-sensitive prostate cancer: CHART trial. Indian J Urol. 2023 Apr-Jun;39(2):171-172. doi: 10.4103/iju.iju_336_22. Epub 2023 Mar 31. PMID: 37304989; PMCID: PMC10249535. 8: Jian T, Zhan Y, Yu Y, Yu K, Hu R, Wang J, Lu J. Combination therapy for high- volume versus low-volume metastatic hormone-sensitive prostate cancer: A systematic review and network meta-analysis. Front Pharmacol. 2023 Apr 20;14:1148021. doi: 10.3389/fphar.2023.1148021. PMID: 37153773; PMCID: PMC10157498. 9: Aragon-Ching JB. Rezvilutamide: yet another androgen receptor pathway inhibitor for metastatic hormone-sensitive prostate cancer? Chin Clin Oncol. 2023 Apr;12(2):12. doi: 10.21037/cco-23-25. Epub 2023 Apr 7. PMID: 37038056. 10: Keam SJ. Rezvilutamide: First Approval. Drugs. 2023 Feb;83(2):189-193. doi: 10.1007/s40265-022-01831-y. PMID: 36630077. 11: Ye D, Gu W, Li J. Rezvilutamide for metastatic hormone-sensitive prostate cancer - Authors' reply. Lancet Oncol. 2022 Nov;23(11):e491. doi: 10.1016/S1470-2045(22)00630-1. PMID: 36328020. 12: Singh K, Mandal S, Nayak P, Das M, Tripathy S. Rezvilutamide for metastatic hormone-sensitive prostate cancer. Lancet Oncol. 2022 Nov;23(11):e490. doi: 10.1016/S1470-2045(22)00624-6. PMID: 36328019. 13: Gu W, Han W, Luo H, Zhou F, He D, Ma L, Guo H, Liang C, Chong T, Jiang J, Chen Z, Wang Y, Zou Q, Tian Y, Xiao J, Huang J, Zhu S, Dong Q, Zhang X, Li H, Yang X, Chen C, Li J, Jin C, Zhang X, Ye D; CHART Investigators. Rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer (CHART): a randomised, open-label, phase 3 trial. Lancet Oncol. 2022 Oct;23(10):1249-1260. doi: 10.1016/S1470-2045(22)00507-1. Epub 2022 Sep 5. PMID: 36075260.